
Saturday, March 30, 2024 11:42:38 AM
Any investigation is unfortunately going to need to start right here as i suspect this is a breach of disclosure required. Most likely a small infraction. There is enough evidence to suggest intent.
Dr. Max Link, PHD (Chairman 2003-2014)
Max Link, Ph.D. has served as the Chairman of our board of directors since October 2003. Dr. Link served as Chairman of the Board and Chief Executive Officer of Centerpulse AG, the largest orthopedics company in Europe, from March 2002 until October 2003, when Centerpulse was acquired by Zimmer Holdings, Inc. Prior to joining Centerpulse,
Max E. Link, Ph.D. has served as the chairman of our board of directors since October 2003. Dr. Link was chairman of the board of directors and Chief Executive Officer of Centerpulse AG, a medical implant company from March 2002 to October 2003. Prior to joining Centerpulse,
Next if you look at the summary of Dr Aaron Hofmann, cofounder of Sintx and a member of the board of Sintx when Sintx first tried to IPO, you'll see inclusion of him being a surgeon designer for Zimmer in the 2007 IPO paperwork. Yet the information about Dr Sonny Bal, also a board member, the fact that hes a surgeon designer for Zimmer in the 2013 IPO paperwork is not disclosed.
Disclosure about Dr. Hofmann, MD in 2007 IPO paperwork
Aaron A. Hofmann, M.D. is our co-founder and has been a member of our board of directors since 1996. Dr. Hofmann is a nationally and internationally recognized orthopedic surgeon, known for his accomplishments in developing total hip and knee replacement systems, innovative surgical approaches in hip and knee surgery and basic research on human bone dynamics. Dr. Hofmann holds 14 patents, many of which are directed at inventions involving hip and knee implants. Since 2003, Dr. Hofmann has been a design surgeon for Zimmer Holdings, Inc., the largest orthopedics company in the world. Dr. Hofmann, working with a team of orthopedic surgeons, helped design Zimmer’s new gender knee specifically designed for women.
Disclosure of Dr Bal, MD in the 2013 IPO paperwork:
B. Sonny Bal, M.D. has served on our board of directors since February 2012. Dr. Bal is Professor & Chief of Adult Reconstruction at the University of Missouri, Columbia, specializing in hip and knee replacement surgery. He also is an Adjunct Professor of Material Sciences at the University of Missouri at Rolla. Dr. Bal is a member of the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons. Dr. Bal received his M.D. degree from Cornell University and an M.B.A. from Northwestern University, and a J.D. from the University of Missouri. Dr. Bal is a licensed attorney and co-founder of the Bal Brenner law firm in North Carolina.
We believe that Dr. Bal’s expertise in orthopedic surgery and his specialty in hip and knee replacement surgery qualifies him to serve on our board of directors.
Per Dr Bals resume:
Designer Surgeon Panel, Zimmer Inc., Warsaw, Indiana, 2002 to present.
Total Joint Reconstruction Clinical Advisory Panel, Amedica Inc., Salt Lake City, UT, 2005 to present.
1. https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 73
2. https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 89
3. https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 74
4. https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 90
5. https://web.archive.org/web/20240316192627/https://hipandknee.com/wp-content/uploads/2014/04/Dr.-Bal-CV.pdf
Could it be that there is a strategy to distract people away from looking at the basic data?
Is all this an exercise to create more and more forum verbiage to drown out any serious discussion of evidence?
Recent SINT News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2024 09:15:30 PM
- SINTX Technologies Secures Patent Allowance for Wide-Ranging Silicon Nitride Biomaterial Applications • GlobeNewswire Inc. • 12/17/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2024 09:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2024 06:15:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/26/2024 11:10:12 AM
- SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment • GlobeNewswire Inc. • 11/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2024 10:13:22 PM
- SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer • GlobeNewswire Inc. • 11/19/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2024 11:15:16 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/15/2024 12:25:52 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/14/2024 09:15:08 PM
- SINTX Technologies Provides Positive Strategic Business Update for Q3 2024 • GlobeNewswire Inc. • 11/14/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 08:50:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 08:30:16 PM
- SINTX Announces Key Executive Promotions: Ryan Bock, PhD, Named Chief Technology Officer and Ann Kutsch Promoted to President of SINTX TA&T • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2024 08:30:31 PM
- Prodways and SINTX Announce Joint Webinar Stay Ahead of the Curve: “Innovations in Ceramic Manufacturing: The Role of 3D Printing” • GlobeNewswire Inc. • 09/20/2024 12:00:00 PM
- SINTX Announces Completion of $3.1 Million ATM Equity Public Offering • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9% • IH Market News • 09/10/2024 10:02:31 AM
- SINTX Receives Notice of Allowance for United States Patent Application for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Significant Cost Reductions, Extended Cash Runway, and Exploration of Strategic Partnerships • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:32:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 01:05:17 PM
- SINTX Technologies Announces Appointment of Eric K. Olson as Chief Executive Officer • GlobeNewswire Inc. • 08/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 08:45:11 PM
51 Labs Expands Sports Nutrition Line with Five New Innovative Products, Company in final phase of name and ticker symbol change • CAFI • Feb 10, 2025 9:00 AM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM
VAYK Project $700K 2024 Revenue with $150K Net Profit • VAYK • Feb 5, 2025 12:43 PM
UAV Corp (UMAV) Kicks Off Landmark "SKY" Hangar Project with Land Clearing at Costin Airport Setting Stage for Q1 2025 Groundbreaking • UMAV • Feb 5, 2025 8:30 AM
HealthLynked Corp. Releases Annual Shareholder Letter Highlighting Recent Product Development and Strategic Vision for the Future • HLYK • Feb 4, 2025 8:00 AM
Wytec Wins Multi-State Government Contract for AI Gunshot Detection • WYTC • Feb 3, 2025 7:16 AM